Antibody Microarray - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Antibody Microarray

The Experts below are selected from a list of 2631 Experts worldwide ranked by ideXlab platform

Christer Wingren – 1st expert on this subject based on the ideXlab platform

  • Biocompatability of surfaces for Antibody Microarrays: Design of macroporous silicon substrates
    , 2020
    Co-Authors: Cornelia Steinhauer, Carl A K Borrebaeck, Anton Ressine, Thomas Laurell, György Marko-varga, Christer Wingren

    Abstract:

    Antibody Microarray is a novel technology with great promise within proteomics. Intense work is under way to evolve this methodology into the high-throughput proteomic research tool needed by the research community. Despite recent advances, there is a growing need for additional highperformance substrates for Antibody Microarrays as well as for protein arrays in general. In this study, we have sucessfully designed novel, highly biocompatible and well-performing silicon-based supports that has the capacity to play a significant role within current and future Antibody and protein Microarray applications within the field of proteomics.

  • technical advances of the recombinant Antibody Microarray technology platform for clinical immunoproteomics
    PLOS ONE, 2016
    Co-Authors: Payam Delfani, Carl Arne Krister Borrebaeck, Linda Dexlin Mellby, Malin Nordstrom, Andreas Holmer, Mattias Ohlsson, Christer Wingren

    Abstract:

    In the quest for deciphering disease-associated biomarkers, high-performing tools for multiplexed protein expression profiling of crude clinical samples will be crucial. Affinity proteomics, mainly represented by Antibody-based Microarrays, have during recent years been established as a proteomic tool providing unique opportunities for parallelized protein expression profiling. But despite the progress, several main technical features and assay procedures remains to be (fully) resolved. Among these issues, the handling of protein Microarray data, i.e. the biostatistics parts, is one of the key features to solve. In this study, we have therefore further optimized, validated, and standardized our in-house designed recombinant Antibody Microarray technology platform. To this end, we addressed the main remaining technical issues (e.g. Antibody quality, array production, sample labelling, and selected assay conditions) and most importantly key biostatistics subjects (e.g. array data pre-processing and biomarker panel condensation). This represents one of the first Antibody array studies in which these key biostatistics subjects have been studied in detail. Here, we thus present the next generation of the recombinant Antibody Microarray technology platform designed for clinical immunoproteomics.

  • Evaluation of Solid Supports for Slide- and Well-Based Recombinant Antibody Microarrays.
    Microarrays, 2016
    Co-Authors: Anna Sandström Gerdtsson, Carl Arne Krister Borrebaeck, Linda Dexlin-mellby, Payam Delfani, Erica Berglund, Christer Wingren

    Abstract:

    Antibody Microarrays have emerged as an important tool within proteomics, enabling multiplexed protein expression profiling in both health and disease. The design and performance of Antibody Microarrays and how they are processed are dependent on several factors, of which the interplay between the antibodies and the solid surfaces plays a central role. In this study, we have taken on the first comprehensive view and evaluated the overall impact of solid surfaces on the recombinant Antibody Microarray design. The results clearly demonstrated the importance of the surface-Antibody interaction and showed the effect of the solid supports on the printing process, the array format of planar arrays (slide- and well-based), the assay performance (spot features, reproducibility, specificity and sensitivity) and assay processing (degree of automation). In the end, two high-end recombinant Antibody Microarray technology platforms were designed, based on slide-based (black polymer) and well-based (clear polymer) arrays, paving the way for future large-scale protein expression profiling efforts.

Carl Arne Krister Borrebaeck – 2nd expert on this subject based on the ideXlab platform

  • technical advances of the recombinant Antibody Microarray technology platform for clinical immunoproteomics
    PLOS ONE, 2016
    Co-Authors: Payam Delfani, Carl Arne Krister Borrebaeck, Linda Dexlin Mellby, Malin Nordstrom, Andreas Holmer, Mattias Ohlsson, Christer Wingren

    Abstract:

    In the quest for deciphering disease-associated biomarkers, high-performing tools for multiplexed protein expression profiling of crude clinical samples will be crucial. Affinity proteomics, mainly represented by Antibody-based Microarrays, have during recent years been established as a proteomic tool providing unique opportunities for parallelized protein expression profiling. But despite the progress, several main technical features and assay procedures remains to be (fully) resolved. Among these issues, the handling of protein Microarray data, i.e. the biostatistics parts, is one of the key features to solve. In this study, we have therefore further optimized, validated, and standardized our in-house designed recombinant Antibody Microarray technology platform. To this end, we addressed the main remaining technical issues (e.g. Antibody quality, array production, sample labelling, and selected assay conditions) and most importantly key biostatistics subjects (e.g. array data pre-processing and biomarker panel condensation). This represents one of the first Antibody array studies in which these key biostatistics subjects have been studied in detail. Here, we thus present the next generation of the recombinant Antibody Microarray technology platform designed for clinical immunoproteomics.

  • Evaluation of Solid Supports for Slide- and Well-Based Recombinant Antibody Microarrays.
    Microarrays, 2016
    Co-Authors: Anna Sandström Gerdtsson, Carl Arne Krister Borrebaeck, Linda Dexlin-mellby, Payam Delfani, Erica Berglund, Christer Wingren

    Abstract:

    Antibody Microarrays have emerged as an important tool within proteomics, enabling multiplexed protein expression profiling in both health and disease. The design and performance of Antibody Microarrays and how they are processed are dependent on several factors, of which the interplay between the antibodies and the solid surfaces plays a central role. In this study, we have taken on the first comprehensive view and evaluated the overall impact of solid surfaces on the recombinant Antibody Microarray design. The results clearly demonstrated the importance of the surface-Antibody interaction and showed the effect of the solid supports on the printing process, the array format of planar arrays (slide- and well-based), the assay performance (spot features, reproducibility, specificity and sensitivity) and assay processing (degree of automation). In the end, two high-end recombinant Antibody Microarray technology platforms were designed, based on slide-based (black polymer) and well-based (clear polymer) arrays, paving the way for future large-scale protein expression profiling efforts.

  • Design of recombinant Antibody Microarrays for urinary proteomics
    Proteomics Clinical Applications, 2012
    Co-Authors: Malin Kristensson, Carl Arne Krister Borrebaeck, Karolina Olsson, Joyce Carlson, Björn Wullt, Gunnar Sturfelt, Christer Wingren

    Abstract:

    PURPOSE: Urinary proteomics has become a key discipline within clinical proteomics for noninvasive diagnosis and monitoring of disease, and biomarker discovery. In order to decipher complex proteomes, high demands will, however, be placed upon the methodology applied. The purpose of this study was to develop a recombinant Antibody Microarray platform for urinary proteomics. EXPERIMENTAL DESIGN: We adopted our previously in-house developed recombinant Antibody Microarray set-up and redesigned the platform for urinary proteomics. In this process, the key Antibody array assay parameters, such as sample handling, sample labeling protocol, and assay conditions, etc, reflecting the unique properties of urine as sample format, were addressed and reoptimized in a step-by-step procedure. RESULTS: In this proof-of-concept study, we have designed the first generation of a recombinant Antibody Microarray technology platform for urinary proteomics. The results showed that multiplexed, sensitive (pg/mL range), and reproducible urine protein expression profiling could be performed targeting directly labeled, nonfractionated urine. CONCLUSION AND CLINICAL RELEVANCE: We have demonstrated that crude, directly labeled urine samples could be profiled in a rapid, reproducible, sensitive, and multiplexed manner after minimal sample prehandling. These findings could potentially pave the way for enhanced urinary proteomics and understanding of renal physiology with implications in both health and disease. (Less)

Brian B Haab – 3rd expert on this subject based on the ideXlab platform

  • Antibody Microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer
    Cancer Research, 2005
    Co-Authors: Randal P Orchekowski, Darren Hamelinck, Lin Li, Ewa Gliwa, Matthew W Vanbrocklin, Jorge A Marrero, George Vande F Woude, Ziding Feng, Randall E Brand, Brian B Haab

    Abstract:

    We used Antibody Microarrays to probe the associations of multiple serum proteins with pancreatic cancer and to explore the use of combined measurements for sample classification. Serum samples from pancreatic cancer patients (n = 61), patients with benign pancreatic disease (n = 31), and healthy control subjects (n = 50) were probed in replicate experiment sets by two-color, rolling circle amplification on Microarrays containing 92 antibodies and control proteins. The antibodies that had reproducibly different binding levels between the patient classes revealed different types of alterations, reflecting inflammation (high C-reactive protein, α-1-antitrypsin, and serum amyloid A), immune response (high IgA), leakage of cell breakdown products (low plasma gelsolin), and possibly altered vitamin K usage or glucose regulation (high protein-induced vitamin K antagonist-II). The accuracy of the most significant Antibody Microarray measurements was confirmed through immunoblot and antigen dilution experiments. A logistic-regression algorithm distinguished the cancer samples from the healthy control samples with a 90% and 93% sensitivity and a 90% and 94% specificity in duplicate experiment sets. The cancer samples were distinguished from the benign disease samples with a 95% and 92% sensitivity and an 88% and 74% specificity in duplicate experiment sets. The classification accuracies were significantly improved over those achieved using individual antibodies. This study furthered the development of Antibody Microarrays for molecular profiling, provided insights into the nature of serum-protein alterations in pancreatic cancer patients, and showed the potential of combined measurements to improve sample classification accuracy.

  • distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon Antibody Microarray analysis
    BMC Cancer, 2005
    Co-Authors: Rork Kuick, Randal P Orchekowski, Brian B Haab, Samir M Hanash, David E Misek, Alissa K Greenberg, Dean E Brenner, Gilbert S Omenn

    Abstract:

    Cancer serum protein profiling by mass spectrometry has uncovered mass profiles that are potentially diagnostic for several common types of cancer. However, direct mass spectrometric profiling has a limited dynamic range and difficulties in providing the identification of the distinctive proteins. We hypothesized that distinctive profiles may result from the differential expression of relatively abundant serum proteins associated with the host response.

  • immunoassay and Antibody Microarray analysis of the hupo plasma proteome project reference specimens systematic variation between sample types and calibration of mass spectrometry data
    Proteomics, 2005
    Co-Authors: Brian B Haab, Bernhard H Geierstanger, George Michailidis, Frank Vitzthum, Sara Forrester, Ryan Okon, Petri Saviranta, Achim Brinker, Martin Sorette, Lorah Perlee

    Abstract:

    Four different immunoassay and Antibody Microarray methods performed at four different sites were used to measure the levels of a broad range of proteins (N = 323 assays; 39, 88, 168, and 28 assays at the respective sites; 237 unique analytes) in the human serum and plasma reference specimens distributed by the Plasma Proteome Project (PPP) of the HUPO. The methods provided a means to (1) assess the level of systematic variation in protein abundances associated with blood preparation methods (serum, citrate-anticoagulated-plasma, EDTA-anticoagulated-plasma, or heparin-anticoagulated-plasma) and (2) evaluate the dependence on concentration of MS-based protein identifications from data sets using the HUPO specimens. Some proteins, particularly cytokines, had highly variable concentrations between the different sample preparations, suggesting specific effects of certain anticoagulants on the stability or availability of these proteins. The linkage of Antibody-based measurements from 66 different analytes with the combined MS/MS data from 18 different laboratories showed that protein detection and the quality of MS data increased with analyte concentration. The conclusions from these initial analyses are that the optimal blood preparation method is variable between analytes and that the discovery of blood proteins by MS can be extended to concentrations below the ng/mL range under certain circumstances.more » Continued developments in Antibody-based methods will further advance the scientific goals of the PPP.« less